Product Description
Hunter-Fleming is developing HF-0220 as a treatment for Alzheimer's Disease. (Sourced from: https://clinicaltrials.gov/ct2/show/record/NCT00357357)
Mechanisms of Action: HPGDS Stimulant
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hunter-Fleming
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Alzheimer Disease|Stroke|Parkinson's Disease|Kidney Diseases|Acute Kidney Injury|Oxidative Stress
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2005-005791-32 |
2005-005791-32 | P2 |
Completed |
Alzheimer Disease|Stroke|Kidney Diseases|Parkinson's Disease|Acute Kidney Injury|Oxidative Stress |
2008-08-11 |
2022-03-12 |
Treatments |
|
NCT00357357 |
HF0220/003 | P2 |
Completed |
Alzheimer Disease |
2008-08-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|